Renal cell carcinoma remains a major clinical challenge in India and worldwide. Recently, studies underscore how KAT2A in RCC progression functions as a pivotal driver of malignancy. Specifically, investigators have uncovered a molecular mechanism involving protein succinylation. This biochemical process regulates tumor growth by stabilizing key proteins.

The Impact of KAT2A in RCC Progression

Researchers observed that KAT2A levels are significantly elevated in renal cancer tissues. High expression of this protein strongly correlates with poor clinical outcomes for patients. When scientists depleted KAT2A in experimental models, they noticed a dramatic reduction in tumor proliferation. Moreover, this depletion effectively halted the epithelial-mesenchymal transition. These findings suggest that KAT2A serves as an essential oncogenic driver.

Stabilizing SERPINE2 via Succinylation

The study further reveals that KAT2A interacts directly with SERPINE2. Specifically, KAT2A promotes the succinylation of SERPINE2 at the lysine 158 residue. This post-translational modification is vital because it prevents the degradation of SERPINE2. Consequently, the stabilized SERPINE2 protein promotes both cell migration and angiogenesis. This axis represents a significant pathway for cancer spreading.

Clinical Implications and Future Directions

Targeting the KAT2A/SERPINE2 pathway offers a promising therapeutic strategy. Since overexpressing SERPINE2 reverses the effects of KAT2A silencing, blocking this interaction is critical. Future treatments might focus on small molecules that inhibit KAT2A-mediated succinylation. Such advancements could improve survival rates for patients with aggressive renal cell carcinoma.

How does KAT2A contribute to kidney cancer?

KAT2A promotes the progression of renal cell carcinoma by increasing the stability of the SERPINE2 protein through a process called succinylation. This leads to increased tumor growth, cell migration, and the formation of new blood vessels.

What is the clinical significance of SERPINE2 succinylation?

Succinylation of SERPINE2 at the lysine 158 residue prevents its degradation. This stabilization allows the protein to drive the epithelial-mesenchymal transition, making the cancer more invasive and difficult to treat.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional opinion. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Liu CC et al. KAT2A Promotes the Progression of Renal Cell Carcinoma by Regulating the Succinylation of SERPINE2. Kaohsiung J Med Sci. 2026 Apr 12. doi: 10.1002/kjm2.70211. PMID: 41968399.

2. Chen X et al. Single-cell RNA-seq integrated with multi-omics reveals SERPINE2 as a target for metastasis in advanced renal cell carcinoma. Cell Death Dis. 2023 Jan 16;14(1):30.

3. Liu Z et al. Oncogenic Chromatin Modifier KAT2A Activates MCT1 to Drive the Glycolytic Process and Tumor Progression in Renal Cell Carcinoma. Front Oncol. 2021;11:665481.